| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
A major concern for cancer vaccines targeting self-tumor antigens is the risk of autoimmune sequelae. Although antitumor immunity correlates with autoimmune disease in some preclinical models, the mechanism(s) linking antitumor immunity and subsequent autoimmune pathology remain(s) to be determined. In the current study, we demonstrated that intradermal (i.d.) immunization with a recombinant adenovirus (Ad) expressing the murine melanoma antigen tyrosinase-related protein 2 (AdmTrp-2) results in a moderate level of tumor protection against the B16F10 murine melanoma without any vitiligo. Similar immunization with an Ad encoding human Trp-2 (AdhTrp-2) resulted in 50-fold greater protective immunity and produced vitiligo in all of the mice, suggesting that the development of autoimmunity may reflect the potency of the vaccine. Interestingly, delivery of AdhTrp-2 by i.m. injection generated protective immunity comparable with that seen in mice that received the vaccine by the i.d. route, but none of the recipients in the i.m. group developed vitiligo. The cellular and humoral responses in the i.m. immunized mice were greater than in the i.d. group; therefore, the lack of vitiligo was not caused by reduced efficacy of the vaccine. These results led us to hypothesize that vaccine-induced vitiligo was associated with local inflammatory responses. Mice immunized i.m. with AdhTrp-2 did develop vitiligo when they subsequently were injected i.d. with either a control Ad vector or complete Freunds adjuvant, suggesting that vitiligo is initiated by some form of trauma within the skin. Our data demonstrated that autoimmune pathology is not an unavoidable outcome of effective cancer vaccines directed against self-tumor antigens.
This article has been cited by other articles:
![]() |
J. D. Finn, J. Bassett, J. B. Millar, N. Grinshtein, T. C. Yang, R. Parsons, C. Evelegh, Y. Wan, R. J. Parks, and J. L. Bramson Persistence of Transgene Expression Influences CD8+ T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus J. Virol., December 1, 2009; 83(23): 12027 - 12036. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Grinshtein, B. Bridle, Y. Wan, and J. L. Bramson Neoadjuvant Vaccination Provides Superior Protection against Tumor Relapse following Surgery Compared with Adjuvant Vaccination Cancer Res., May 1, 2009; 69(9): 3979 - 3985. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Schuler, E. Contassot, M. Irla, S. Hugues, O. Preynat-Seauve, F. Beermann, A. Donda, L.E. French, and B. Huard Direct Presentation of a Melanocyte-Associated Antigen in Peripheral Lymph Nodes Induces Cytotoxic CD8+ T Cells Cancer Res., October 15, 2008; 68(20): 8410 - 8418. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. King, J. Waxman, and H. Stauss Advances in tumour immunotherapy QJM, September 1, 2008; 101(9): 675 - 683. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Luketic, J. Delanghe, P. T. Sobol, P. Yang, E. Frotten, K. L. Mossman, J. Gauldie, J. Bramson, and Y. Wan Antigen Presentation by Exosomes Released from Peptide-Pulsed Dendritic Cells Is not Suppressed by the Presence of Active CTL J. Immunol., October 15, 2007; 179(8): 5024 - 5032. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kianizad, L. A. Marshall, N. Grinshtein, D. Bernard, R. Margl, S. Cheng, F. Beermann, Y. Wan, and J. Bramson Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope Cancer Res., July 1, 2007; 67(13): 6459 - 6467. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yagi, H. Hashizume, T. Horibe, Y. Yoshinari, M. Hata, A. Ohshima, T. Ito, M. Takigawa, A. Shibaki, H. Shimizu, et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous Peptide immunization. Cancer Res., October 15, 2006; 66(20): 10136 - 10144. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lambe, J. C. H. Leung, T. Bouriez-Jones, K. Silver, K. Makinen, T. L. Crockford, H. Ferry, J. V. Forrester, and R. J. Cornall CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions. J. Immunol., September 1, 2006; 177(5): 3055 - 3062. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-C. Yang, J. Millar, T. Groves, N. Grinshtein, R. Parsons, S. Takenaka, Y. Wan, and J. L. Bramson The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity J. Immunol., January 1, 2006; 176(1): 200 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Santosuosso, X. Zhang, S. McCormick, J. Wang, M. Hitt, and Z. Xing Mechanisms of Mucosal and Parenteral Tuberculosis Vaccinations: Adenoviral-Based Mucosal Immunization Preferentially Elicits Sustained Accumulation of Immune Protective CD4 and CD8 T Cells within the Airway Lumen J. Immunol., June 15, 2005; 174(12): 7986 - 7994. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |